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Abstract
Endoplasmic reticulum (ER) stress elicits the unfolded protein response (UPR), initially aimed at coping with the stress, but
triggering cell death upon further stress. ER stress induces the C/EBP-H variant Liver-enriched Activating Protein (LAP),
followed by the dominant-negative variant, Liver Inhibitory Protein (LIP). However, the distinct role of LAP and LIP in ER
stress is unknown. We found that the kinetics of the ER stress-induced expression of LIP overlapped with that of the cell
death in mouse B16 melanoma cells. Furthermore, inducible over-expression of LIP augmented ER stress-triggered cell
death whereas over-expression of LAP attenuated cell death. Similar results were obtained in human 293T cells. Limited
vasculature in tumors triggers hypoxia, nutrient shortage and accumulation of toxic metabolites, all of which eliciting
continuous ER stress. We found that LAP promoted and LIP inhibited B16 melanoma tumor progression without affecting
angiogenesis or accelerating the cell cycle. Rather, LAP attenuated, whereas LIP augmented tumor ER stress. We therefore
suggest that C/EBP-H regulates the transition from the protective to the death–promoting phase of the UPR. We further
suggest that the over-expression of LAP observed in many solid tumors promotes tumor progression by attenuating ER
stress–triggered tumor cell death.
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Introduction
The endoplasmic reticulum is the site of post-translational
processing (refolding, glycosylation and oxidative disulfide bond
formation) of secreted and cytoplasmic membrane proteins. The
ER is also the site of membrane biogenesis and helps maintain
intracellular calcium ion and lipid homeostasis. Accumulation of
client proteins or misfolded proteins, overload of free cholesterol,
perturbations in calcium ion homeostasis, oxidative stress and
xenobiotic toxins rapidly induce ER stress, which triggers an
evolutionarily conserved cellular response, termed the Unfolded
Protein Response (UPR) [1]. Initial UPR is aimed at coping with
the stress by inducing ER chaperones and attenuating general
protein translation. Persistent ER stress induces the expression of
the C/EBP homologous protein (CHOP), which initiates the cell
death machinery [2]. The mechanisms that regulate the transition
from the protective phase to the death–promoting phase of the
UPR are not known.
ER stress induces the expression of the transcription factor C/
EBP-b [3,4] but there are contradictory reports on the role of C/
EBP-b in ER stress. Embryonic fibroblasts from C/EBP-b-deficient
mice are less sensitive to ER stress–mediated cell death [5,6]. In
contrast, other cell types from these mice exhibit enhanced
sensitivity to cell death triggered by growth factor deficiency,
exposure to toxins or carcinogens and other stresses [7–11]. Other
studies found that C/EBP-b is pro-apoptotic[5,12–16]. Because the
common C/EBP-b mRNA encodes both transcriptional activators
(LAP* and LAP) and a dominant-negative, truncated form (LIP)
[17], these opposing observations may be related to the LIP:LAP
ratio. Furthermore, the LIP:LAP ratio is not constant, increasing in
time, as the ER stress continues [18]. Therefore, further studies are
required to determine the specific role of LAP and LIP in the
cellular response to ER stress.
ER stress has been associated with many diseases, where it leads
to cell death [1,19]. Because neovascularization lags behind tumor
cell proliferation, solid tumors are under continuous ER stress due
to nutrient shortage, accumulation of cytotoxic metabolites and
hypoxia. However, the cells adapt to this stress through the
constitutive activation of the protective phase of the UPR
(reviewed in: [2,20–22]). So far, the mechanisms that mediate
this adaptation are not fully characterized. The various C/EBP-b
isoforms are over-expressed in many types of tumors [8,23–32],
but the specific role of LAP and LIP in tumor progression has not
been studied. Recently, C/EBP-b was shown to support the
survival of neurons under hypoxic conditions, which also trigger
ER stress [33]; however, in these studies, both LAP and LIP were
either over-expressed or were deleted, and therefore their
individual function is not known.
To study the role of C/EBP-b LAP and LIP in ER stress and in
tumor progression, we utilized B16 melanoma clones that
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inhibiting endogenous LAP activity, as well as other clones that
inducibly over-express LAP. Our findings suggest that C/EBP-b
has a key role in regulating the transition from protective to death
promoting UPR; LAP attenuates and LIP augments cell death,
and LAP contributes to tumor progression by attenuating ER
stress and subsequent cell death.
Results
LAP Attenuates and LIP Augments ER Stress-Triggered
Cell Death
To study the role of LAP to LIP ratio in ER stress-triggered cell
death, we used the specific inducers of ER stress tunicamycin (Tm)
and thapsigargin (Tg) and murine B16 melanoma clones that
inducibly express either LAP or LIP [34]. Clone F10.9-3 constitu-
tively expresses the Tet repressor and carries a vector with a
bidirectional inducible promoter encoding wt LAP and GFP.
Immunoblotting with an antibody directed against the common C-
terminus of the various C/EBP b isoforms revealed that doxycycline
induced only LAP in Clone F10.9-3 (Figure S1). Similarly, Clone
F10.9-4 expressed only LIP, which is the dominant-negative form of
LAP (Figure S1). Initially, we triggered ER stress in un-induced cells
a n dc o m p a r e dt h ep r o g r e s s i o no fc e l ld e a t ha n dt h ee x p r e s s i o no f
endogenous LAP and LIP. Cell detachment and death started 4–6 h
after addition of tunicamycin, as determined quantitatively by
staining of the remaining attached cells with Crystal Violet
(Figures 1A & B, solid lines). Basal LAP and LIP were
undetectable by immunoblotting. As previously reported [18], LAP
expression was apparent already at 3 h, whereas LIP appeared at 6 h
(Figure 1C). Thus, initiation and further progression of cell death
was temporally associated with endogenous LIP levels.
To further evaluate the role of LAP and LIP in determining the
cell fate under ER stress, we studied the impact of their over-
expression on the progression of cell death, as determined by
Neutral Red staining. Over-expression of LIP in the F10.9-4 cells
prior to addition of tunicamycin abolished the 4 h ‘‘grace period’’,
leading to a statistically significant increase of cell death by 4 h
(P,0.009, N=4), as well as at all later time points (P,0.01, N=4;
Figure 1A, dashed line). No cell death was seen upon LIP
expression in the absence of ER stress (data not shown). Over-
expression of LAP had no significant effect in the first 4 h, but
significantly attenuated cell death at all other time points (P,0.01–
0.03; N=4; Figure 1B, dashed line). These observations
demonstrated that LAP attenuates and LIP augments ER stress-
triggered cell death. Since both LAP and LIP were induced past
the first 5 h, we evaluated their combined effect on cell viability by
siRNA knockdown. Silencing of both LAP and LIP expression
significantly augmented the tunicamycin-triggered death of F10.9-
3 cells as determined by viability staining with Neutral Red
(P,0.0001; N=9; Figure 1D). Because LIP lacks a trans-
activation domain, it probably augmented cell death by inhibiting
ER stress-induced LAP.
Microscopic observation of Crystal Violet–stained cultures
further demonstrated that LIP over-expression augmented thapsi-
gargin or tunicamycin–triggered cell death at 24 h (Figure 2A). In
contrast, over-expression of LAP attenuated thapsigargin or
tunicamycin–triggered cell death, as determined at 24 and 48 h,
respectively (Figure 2B). The impact of C/EBP-b on tunicamy-
cin–induced cell death was further determined quantitatively by
viability staining with Neutral Red. Over-expression of LIP
significantly augmented tunicamycin–induced cell death
(P,0.0001, N=9), whereas over-expression of LAP significantly
attenuated cell death (P,0.0001, N=9; Figure 2C, D,
respectively). A similar increase in ER stress-triggered cell death
was obtained in three other independent F10.9 LIP-expressing
sub-clones following induction with doxycycline. Similarly, ER
stress–triggered cell death was attenuated in four other indepen-
dent F10.9 LAP-expressing sub-clones following doxycycline (data
not shown). The enhancement of cell death by LIP was dose–
dependent and apparent upon induction with $100 ng/ml
doxycycline (Figure S2A). Similarly, the attenuation of cell death
was dose–dependent and apparent upon induction of LAP with
$100 ng/ml doxycycline (Figure S2B).
Microscopic evaluation of Annexin V staining of tunicamycin-
challenged cultures revealed lack of apoptotic cells within 24 h of
treatment (Figure S3A). Rather, tunicamycin triggered cell
rounding and detachment from the plate. The detached cells
were dead or dying, as determined by propidium iodide staining
(Figure S3B). Some of the tunicamycin-treated cells remained
attached to the plate and although they were propidium iodide
negative, they appeared to be dead, as they were condensed and
rounded (Figure S3C, left panels). Unlike control cells, the LAP–
over expressing F10.9-3 cells survived the tunicamycin treatment,
they remained attached to the plate and appeared viable (Figure
S3C, right panels). Furthermore, they propagated normally after
removal of the ER stress triggers (data not shown). Based upon
these observations we concluded that the ER stress-induced LAP
attenuated cell death, whereas LIP augmented cell death, probably
by inhibiting or re-directing the pro-survival activity of LAP.
To determine how general is the role of C/EBP-b in ER stress,
we studied the impact of C/EBP-b over-expression and knockout
in additional cell types. Over-expression of LAP in human 293T
cells by transfection with an expression vector designed to encode
LAP only (pcLAP, Figure S4A) rendered the cells significantly
more resistant to tunycamycin-triggered cell death (P,0.0007,
N=4,Figure S4B). In contrast, over-expression of LIP in human
293T cells by transfection with an expression vector encoding only
the LIP open reading frame (pcLIP, Figure S4A) rendered the
cells significantly more sensitive to tunycamycin-triggered cell
death (P,0.003, N=4, Figure S4B).
Knockdown of C/EBP-b in human HeLa cells by siRNAs
specific to C/EBP-b led to efficient silencing of its expression at
48 h, as determined by RT-PCR and immunoblotting with an
antibody directed against a common C-terminal peptide of C/
EBP-b (Figure S4C; left and right panels, respectively). The
silencing of C/EBP-b increased the sensitivity of HeLa cells to ER
stress–triggered cell death (Figure S4D), leading to a statistically
significant decrease in the cell counts (P,0.0003, N=4, Figure
S4E). Over-expression of LAP in human HeLa cells by
transfection with pcLAP rendered the cells significantly more
resistant to tunicamycin-triggered cell death (P,0.001, N=6,
Figure S4F). In contrast with all other experiments, over-
expression of LIP in HeLa cells by pcLIP also rendered the cells
more resistant by 13% to tunicamycin-triggered cell death
(P,0.002, N=5). Yet, all other results suggest a general role for
C/EBP-b in modulating ER stress–triggered cell death.
Attenuation of Cell Death by LAP Prevails Over Its
Inhibitory Effect on the Cell Cycle
To study the mechanism by which LAP and LIP regulate the
cell fate upon ER stress, we first determined the impact of LAP
over-expression on the cell cycle. As previously reported [35],
treatment of the B16 melanoma clone F10.9-3 with tunicamycin
abolished DNA synthesis, leading to cell cycle arrest, as
determined by flow cytometry of propidium iodide–stained cells
(Figure 3 compare the two left panels). Over-expression of LAP in
F10.9-3 cells for 24 h prior to treatment with tunicamycin or
C/EBP-b Regulates Cell Death
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9516Figure 1. Kinetics and dose-response of ER stress–induced LIP, LAP and cell death. (A) F10.9-4 cells (30,000/well) were cultured in 96-well
plates with or without doxycycline (1.2 mg/ml, 24 h). Tunicamycin (0.75 mg/ml) was then added, and the cell number was determined following
fixation and crystal violet staining at the indicated times. OD was converted to cell counts using a calibration curve. Data are presented as mean6SD
from four replicates. (B) F10.9-3 cells (40,000/well) were cultured and treated with doxycycline and tunicamycin as described in (A). Data are
presented as mean6SD from four replicates. (C) F10.9 cells (1.5610
6) were seeded in 9 cm plates for 24 h. Tunicamycin was then added to the cells
and cell extracts were prepared at the indicated times. Extracts were resolved by SDS-PAGE and immunoblotted with an antibody directed against a
common C-terminal peptide of C/EBP-b. NS: non-specific band, serving as a loading control. The blot is a representative of three replicates. (D) F10.9-3
cells were transfected with the indicated siRNA and seeded in 96 well plates (2610
4/well). Tunicamycin (Tm) was added after 48 h and viability was
determined by Neutral Red staining after 27 h. Data are average6SD of cell counts in 9 replicates. inset: Silencing efficiency as determined by
immunoblotting of C/EBP-b LAP (I) vs. actin (II) of cell extracts treated with control siRNA (1) or C/EBP-b siRNA (2).
doi:10.1371/journal.pone.0009516.g001
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9516Figure 2. LIP augments and LAP attenuates ER stress–triggered cell death. (A) F10.9-4 cells (2610
4/well) were cultured in 96-well plates in
media without (Ctrl) or with (LIP) doxycycline. The cells were then treated with diluent (Ctrl), thapsigargin (Tg, 48 h) or tunicamycin (Tm, 24 h). The
plates were stained with crystal violet and photographed (left panels, 1x; right panels, light microscopy). The photographs are representative of 5
replicates. Bar=0.5 mm. (B) F10.9-3 cells (4610
5/well) were cultured in 6-well plates without (Ctrl) or with (LAP) doxycycline. Diluent (Ctrl),
thapsigargin or tunicamycin were then added. The plates were then stained with crystal violet and photographed as in (A). The photographs are
representative of 5 replicates. Bar=0.5 mm. (C) F10.9-4 cells (1.5610
4/well) were cultured in 96-well plates without (Ctrl) or with (LIP) doxycycline.
Diluent or tunicamycin were then added. After additional 24 h, the viable cell counts were determined by staining with Neutral Red and the percent
survival was calculated. Percent survival was determined on averages of 9 pairs of replicates. (D) F10.9-3 cells (1.5610
4/well) were cultured in 96-well
plates without (Ctrl) or with (LAP) doxycycline. Diluent or tunicamycin were then added. The cells were stained and percent survival was calculated as
in (C).
doi:10.1371/journal.pone.0009516.g002
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lowered the extent of cell proliferation in control cells, reducing
the number of cells in S phase by about 25% and increasing the
percentage of cells in the G0/G1 phase (Figure 3, top panels).
The observed LAP-mediated inhibition of cell proliferation was
consistent with a previous study on the impact of LAP (LAP-2) on
cell cycle progression [26]. Hence, we concluded that the pro-
survival activity of LAP must have been the outcome of its effect
on cell death rather than on the cell cycle. Furthermore, the
attenuation of cell death by LAP under stress prevailed over its
inhibitory effect on unstressed cell proliferation. We therefore
focused on the impact of LAP and LIP on cell death mechanisms.
LAP Attenuated Necrotic Cell Death by Lowering CHOP
Expression
Although tunicamycin triggered rounding, detachment and
death of the F10.9 cells, we were unable to detect either annexin
V-positive cells (Figure S3A) or cleaved caspase 3 in the cell
extracts (Figure 4A). This result was also in accordance with the
absence of sub G0 cell population, as revealed by flow cytometry
(Figure 3). Rather, we found that ER stress triggered the release
of High-Mobility Group Box 1 (HMGB1) to the culture
supernatant, indicating a mechanism involving necrotic cell death
[36]. Furthermore, over-expression of LAP attenuated the release
of HMGB1 (Figure 4B). Therefore, we concluded that LAP
attenuates the ER stress-triggered necrosis of F10.9 cells. The lack
of annexin V staining minimizes the possibility that necrosis was
initiated by an early stage of a caspase 3-independent apoptotic
mechanism. To further study the mechanism by which LAP
modulates ER stress, we measured the effect of its over-expression
on the early and late ER stress markers Binding Protein (BiP;
GRP78) and CHOP in tunicamycin-treated F10.9-3 cells.
Immunoblot analysis revealed that over-expression of LAP did
not lower the ER stress–induced chaperone BiP. In contrast, LAP
reduced the level of the death executor CHOP (Figure 4C).
These results indicated that LAP does not affect the early
protective phase of the UPR. Rather, LAP attenuates the late,
death-promoting phase of the UPR.
LAP Promotes Tumor Progression by Attenuating Cell
Death
To study the role of LAP in tumor progression, we inoculated
mice subcutaneously either with F10.9-4 cells or with F10.9-3 cells
and induced LIP or LAP expression, respectively, by including
doxycycline (Doxy; 1 mg/ml) in the drinking water. Palpable
tumors were detected in the mice after 8 days and differences in
tumor mass were apparent by day 13. Therefore tumors in one
group of mice were isolated and examined at day 8 and at day 13
Figure 3. Cell cycle analysis of F10.9-3 cells. F10.9-3 cells (2610
6) were cultured in 9 cm plates with or without doxycycline to induce LAP. The
cells were then challenged with tunicamycin, collected, permeabilized using 70% ethanol at 220uC, stained with propidium iodide and analyzed
using flow cytometry. The graphs are representatives of three replicate experiments.
doi:10.1371/journal.pone.0009516.g003
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over-expression of LIP led to a significant attenuation of tumor
growth as determined at day 13 (P,0.005, N=9). In contrast,
over-expression of LAP significantly increased the tumor mass by
fourfold over a 5 day period (P,0.001, N=10; Figure 5).
To distinguish between the possible effects of LAP on tumor cell
proliferation and cell death we stained tumor sections with the
proliferationmarkerKi-67 [37]. The percentof Ki67 (dividing) cells
in tumors isolated at day 8 was not significantly affected by over-
expression of LIP (P=0.570, N=4; Figure 6A, top panels). In
accordance with our results in vitro (Figure 3), over-expression of
LAP in the tumor resulted in a statistically significant reduction of
Ki67-positive cells (P,0.03, N=4; Figure 6A, bottom panels).
Hence, the increase in the tumor mass upon induction of LAP must
have been due to reduction in cell death, which apparently
Figure 4. ER stress triggers caspase3–independent cell death,
which is attenuated by LAP. (A) F10.9-3 cells (2610
6)i n9c mp l a t e s
were challenged either with tunicamycin for 24 & 48 h or with murine IFN-c
and TNF-a(1000 IU/ml and 100 ng/ml, respectively, 48 h; used as a positive
control for caspase 3-mediated apoptosis). Cell extracts were analyzed by
immunoblotting using antibodies to cleaved caspase 3. (B) F10.9-3 cells in
9 cm plates were cultured for 24 h with or without doxycycline (Doxy). The
cells were then treated with diluent (Ctrl) or tunicamycin (Tm, 0.25 mg/ml,
24 h). Clarified culture supernatants of the cell cultures (50 ml) were
subjected to immunoblotting with antibodies to HMGB1. (C) Total cellular
proteins of the cells from (B) were isolated at 24 h and subjected to
immunoblot analysis with the indicated antibodies. Each of the immuno-
blot shown is a representative of three replicate experiments.
doi:10.1371/journal.pone.0009516.g004
Figure 5. LAP increases B16 melanoma tumor mass. (A) C57/BL6
mice were inoculated with F10.9-4 cells. Dominant negative LIP was
induced by doxycycline in the drinking water. Mice were euthanized at day
8 or 13, and the tumors were removed and weighed. Data are presented as
the average6SD of 9 tumors. Inset: Photograph of representative tumors.
(B) C57/BL6 mice were inoculated with F10.9-3 cells. LAP was induced by
doxycycline in the drinking water. Mice were euthanized at day 8 or 13, and
the tumors were removed and weighed. Data are presented as the
average6SD of 10 tumors. Inset: Photograph of representative tumors.
doi:10.1371/journal.pone.0009516.g005
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were abundant in the tumor sections (Figure 6B, block arrows).
Therefore, we focused our study on the impact of LAP and LIP on
the extent of tumor cell death. Immunostaining of tumor sections
isolated at day 8 revealed a rather low frequency (#3%) of cleaved
caspase 3-positive cells in control tumors and in tumors expressing
either LAP or LIP. Furthermore, expression of either LIP or LAP
had no statistically significant effect on the fraction of the cleaved
caspase 3-positive cells (P=0.64, N=3 and P=0.52, N=3 for LIP
and LAP, respectively; Figure 7). Hence, similarly to the in vitro
study (Figure4), spontaneousB16 melanomacelldeath invivowas
probably mediated by a caspase-3 independent mechanism.
LAP Attenuates Hypoxia–and Nutrient
Deprivation–Triggered Cell Death
LAP could attenuate tumor cell death indirectly by inducing
angiogenic factors or by modulating intrinsic tumor cell functions.
Staining of frozen tumor sections with antibodies to the
endothelial cell marker CD31 did not reveal a significant effect
of LAP on the extent of tumor vascularization (Figure 8). Hence,
we concluded that LAP attenuated mechanisms that trigger tumor
cell death or rendered the cells more resistant to such mechanisms.
We therefore studied the impact of LAP on B16 cell survival upon
triggering ER stress by the tumor-related stressors hypoxia and
nutrient deprivation. To this end, we employed extreme hypoxic
conditions (1% oxygen) or media completely lacking nutrients
(serum-free Earle’s Balanced Salt Solution (EBSS)) in a series of in
vitro studies. As expected, hypoxia or nutrient deprivation led to
massive ER stress-triggered cell death (Figure 9). Over-expression
of LAP significantly attenuated the extent of cell death (P,0.0001,
N=4 for hypoxia; P,0.0002, N=4 for starvation; determined by
measuring the relative Crystal Violet staining intensity; Figure 9).
These results were in accordance with the impact of LAP on the
specific inducers of ER stress tunicamycin and thapsigargin.
Figure 6. Ki-67 and H&E staining of tumor sections. (A) Sections of control F10.9-4 tumors and dominant negative C/EBP-b LIP–expressing
F10.9-4 tumors of similar sizes, isolated at day 8, were immunostained with an antibody against Ki-67, and nuclei were counter-stained with Hoechst
33258 (top left and right panels, respectively). Percent Ki67-positive nuclei were determined by counting sections from 4 control and 4 LIP-expressing
tumors (71–94 nuclei/field, middle top panel). Sections of control F10.9-3 tumors and LAP-expressing F10.9-3 tumors of similar sizes, isolated at day 8
(bottom left and right panels, respectively), were prepared and stained as above. Percent Ki67-positive nuclei were determined by counting sections
from 4 control and 4 LAP-expressing tumors (60–107 nuclei/field, middle bottom panel). Representative images of sections from the four tumors are
shown. Bar=0.1 mm. (B) Sections of control F10.9-3 tumors and LAP-expressing F10.9-3 tumors of a similar size, isolated at day 8, were stained with
hematoxylin and eosin. The block arrows indicate necrotic areas. Bar=0.1 mm. The photograph is a representative of sections from 5 tumors.
doi:10.1371/journal.pone.0009516.g006
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Hypoxia, nutrient deprivation and accumulation of toxic metab-
olites lead to tumor cell death by triggering ER stress. Therefore, we
examined the impact of LAP inhibition or over-expression on ER
stressinthetumors.Tothisend,weimmunostainedsectionsobtained
from tumors of similar size at day 8 for two ERstressmarkers,TRIB3
and HERPUD [38,39]. Inhibition of endogenous LAP by over-
expression of LIP significantly increased the expression of TRIB3
(P,0.0003, N=3) and HERPUD (P,0.0005, N=5), whereas over-
expression of LAP reduced the expression of these markers (P,0.01,
N=3forTRIB3;P,0.01, N=4 for HERPUD) (Figure 10). The
reduced expression of the CHOP-induced death executor TRIB3
indicated that the tumor progression and the inhibition of ER stress–
triggered cell death in vitro share a common mechanism, mediated
by C/EBP-b.
Discussion
Tumor progression depends on the ability of its cells to adapt to
ER stress due to lagging development of the neovasculature, which
lead to nutrient limitation, impaired clearance of toxic metabolites
and hypoxia. The combination of these constraints with the
inherent hypermutability of cancer cells selects for cells resistant to
ER stress–triggered cell death. Such resistance may be achieved by
constitutive activation of the protective phase of the UPR [40,41].
Despite significant advances in recent years [22], many features of
tumor cell resistance to ER stress are unknown. The present study
demonstrates the critical role of resistance to ER stress in tumor
progression and shows that C/EBP-b modulates the ER stress-
triggered cell death. We suggest that selection of LAP over-
expressing cells, as reported in many types of cancers, enables the
growing tumor to thrive despite continuous exposure to an ER
stress–inducing environment. Although further studies are re-
quired to confirm the mode of action of C/EBP-b in the tumor, it
is tempting to speculate that LAP or certain LAP-induced genes
may serve as potential therapeutic targets for cancer and for other
ER stress–mediated diseases.
The reported induction of C/EBP-b by ER stress [3] provided a
general physiological framework for these studies on top of the
tumor-related pathophysiology. Earlier studies with C/EBP-b-
deficient cells and mice yielded conflicting results on the role of C/
EBP-b in cell survival and death. Over-expression of LAP has
been described in several cancer cell lines and was implicated in
oncogenic transformation [25,42]. Other studies found that C/
EBP-b was pro-apoptotic [43,44]. Such conflicting observations
are not unexpected, as the single C/EBP-b mRNA is alternatively
translated to both transcriptional activators (LAP* and LAP) and
to their natural, dominant-negative inhibitor (LIP). Interactions of
LAP and LIP with other transcription factors may also explain
these conflicting results, as seen by us upon over-expression of LIP
in HeLa cells. However, by using B16 melanoma clones that
individually express either inducible LAP or LIP (Figure S1), we
were able to determine the specific impact of LAP and LIP on the
cell fate under ER stress in vitro and in tumors in vivo. Induction
of LIP results in suppression of endogenous LAP activity.
Induction of LAP, on the other hand, mimics the over-expression
seen in many tumors.
Our finding that LAP attenuated whereas LIP augmented ER
stress–triggered cell death in vitro (Figures 1, 2 &S2) correlated
with the observed fourfold increase in the size of LAP-expressing
tumors during days 8-13 and the mirror image fourfold decrease in
size of LIP-expressing tumors (Figure 5). The protective effect
exerted by LAP in cells exposed to nutrient deprivation or hypoxia
further supports this correlation (Figure 9). The inhibition of the
expression of death executor CHOP by LAP under ER stress
(Figure 4) provides one mechanism by which LAP attenuated ER
Figure 7. Cleaved caspase-3 staining of tumor sections. Sections of control F10.9-4 tumors and LIP-expressing F10.9-4 tumors of similar sizes,
isolated at day 8 (top panels), were immunostained with an antibody against cleaved caspase 3, and nuclei were counter-stained with Hoechst 33258.
The fraction of cleaved-caspase3-positive cells was determined by counting sections from 3 control and 3 LIP-expressing tumors (57–94 cells/field,
middle top panel). Sections of control F10.9-3 tumors and LAP-expressing F10.9-3 tumors of similar sizes, isolated at day 8 (bottom panels), were
prepared and stained as above. The fraction of cleaved-caspase3-positive cells was determined by counting sections from 3 control and 3 LAP-
expressing tumors (67–109 cells/field, middle bottom panel). Representative images of sections from 3 tumors are shown. Bar=0.1 mm.
doi:10.1371/journal.pone.0009516.g007
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is induced by CHOP, our finding that LAP attenuated and LIP
augmented the expression of TRIB3 in the tumor (Figure 10A)
suggests that LAP promotes tumor progression by attenuating
CHOP-mediated cell death. By performing knockdown and over-
expression studies in two other human cell types (Figure S4)w e
demonstrated the general role of LAP and LIP in modulating the
resistance to ER stress-triggered cell death. A previous study
demonstrated that C/EBP-b null mice (lacking both LAP and LIP)
are completely refractory to generation of skin tumors upon
exposure to a carcinogen [8]. Our findings further show that C/
EBP-b promotes the progression of an established tumor by
attenuating cell death, implicating ER stress in the process.
Our findings suggest that changes in the LAP-LIP ratio control
the transition from the early, protective UPR to its late, death–
promoting phase. Others [18] and we observed that ER stress
initially triggered the expression of LAP, whereas extended ER
stress led to expression of both LAP and LIP (Figure 1). C/EBP-b
was found to be constitutively bound to the CHOP promoter at
the common C/EBP-ATF4 site, inhibiting CHOP expression in rat
cells [45]. Our findings that LAP attenuated the expression of
CHOP and its downstream target TRIB3 (Figures 4C &10A)
suggest that LAP rather than LIP is the constitutive transcriptional
inhibitor of CHOP. Thus, LIP may relieve the transcription
inhibition of LAP by forming a futile LAP-LIP heterodimer and
thereby triggering cell death. Alternatively or additionally, such a
LAP-LIP heterodimer may trigger cell death in a manner
analogous to the proposed action of the LAP-CHOP heterodimer
[5]. Regardless of the exact mechanism, this study demonstrates
that LAP inhibits the death-promoting phase of the UPR whereas
in most cases LIP promotes ER stress–triggered cell death.
Establishing the impact of LAP and LIP on gene expression under
ER stress will further clarify the mechanism by which LAP
attenuates cell death.
Materials and Methods
Ethics Statement
The Weizmann Institute Animal Care and Use Committee
approved all studies in mice, according to institutional guidelines
and Israeli law.
Cells and Reagents
The murine B16 melanoma clones, F10.9-3 and F10.9-4, were
derived from the parental cell line B16-F10 (ATCC CRL-6475)
and were kindly provided by M. Revel and J. Chebath (Weizmann
Institute of Science) [34]. Human cervical carcinoma HeLa cells
(CCL-2.1) and human embryonic kidney cells (HEK 293T) were
obtained from the American Type Culture Collection (ATCC),
Manassas, VA. Cell culture media were supplemented with 10%
FBS and antibiotics (DMEM-10 and MEM-10) and cells were
grown in humidified 8% CO2 incubators at 37uC. Expression of
LAP and LIP was induced in the F10.9-3 and F10.9-4 cells,
respectively by doxycycline (Doxy, 1 mg/ml, 24 h) unless otherwise
stated. ER stress was elicited by treatment with tunicamycin
(0.75 mg/ml, 24 h) or thapsigargin (50 nM, 48 h) unless otherwise
Figure 8. Vascularization of control and LIP–or LAP–expressing tumors. Sections of control and LIP–expressing tumors of similar sizes,
isolated at day 8, (top panels) were stained with CD31 antibodies, and nuclei were counter-stained with Hoechst 33258. Sections of control and LAP–
expressing tumors of similar sizes, isolated at day 8 (bottom panels), were stained with CD31 antibodies. The photographs are representatives of
sections obtained from 3 tumors from each one of the four treatment groups.
doi:10.1371/journal.pone.0009516.g008
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purchased from Santa Cruz Biotechnology (Santa Cruz, CA); the
TRIB3 antibody (ST1032) was from Calbiochem (San Diego, CA);
the Ki-67 antibody (clone TEC-3) was from DakoCytomation
(Copenhagen, Denmark); the cleaved caspase 3 antibody (Asp 175)
was from Cell Signaling (Danvers, MA); the HERPUD antibody
was from Protein Tech Group (Chicago, IL), the rat anti-mouse
CD31 (PECAM-1) and BiP/GRP78 antibodies were from BD
Pharmingen, (San Diego, CA), the HMGB1 antibody (H9539) was
from Sigma-Aldrich (Rehovot, Israel) and the Cy3-conjugated
streptavidin, biotin-SP–conjugated AffiniPure donkey anti-rabbit
IgG and biotin-SP–conjugated goat anti-mouse IgG antibodies
were from Jackson ImmunoResearch (Baltimore, PA). All other
reagents were purchased from Sigma-Aldrich (Rehovot, Israel).
Tumor Generation and Immunohistochemistry
C57/BL6 mice were inoculated subcutaneously with F10.9-3 or
F10.9-4 cells (100 ml medium, containing 5610
5 cells mixed with
100 ml Matrigel). Doxycycline (1 mg/ml) was added to the drinking
water for the induction of LAP and LIP. Mice (10 per group) were
euthanized at day 8 or 13, and tumors were resected, weighed,
photographed and either fixed in 10% formaldehyde or frozen
before sections were prepared. The significance of differences in the
tumor mass was determined by Student’s t-test of independent
samples. The paraffin sections were immunostained with antibodies
to Ki-67, cleaved caspase 3, TRIB3 and HERPUD, followed by
incubation with biotin-conjugated antibodies and Cy3-conjugated
streptavidin. Cell nuclei in tumor slices and in cultures were stained
withHoechst 33258(5 mg/ml; excitationat 365 nm and emission at
470 nm). ForCD31 immunostaining, tumor tissues were embedded
inOCTand werefrozenat280uCforcryosectioning.Afterfixation
in 100% acetone (220uC, 20 min), slides were immunostained as
described above.
Quantitative Measurment of the Immunostains
The percentage of proliferating cells was determined by counting
ki67-positive nuclei and dividing by the total number of (Hoechst
33258-stained) nuclei. The fraction of cleaved caspase 3 cells was
similarly determined. The staining intensity of TRIB3 and
HERPUD was determined by the histogram function of The
Photoshop program (red channel) and normalized to the staining
intensity of the nuclei (blue channel) in the same field. The
Figure 9. LAP attenuates hypoxia–and nutrient deprivation–triggered cell death. (A) F10.9-3 cells (4610
5/well) were cultured in 6-well
plates in media without (Ctrl) or with (LAP) doxycycline. The plates were then cultured for 53 h, either under normoxia (8% CO2 in air) or under
hypoxia (1% O2 and 8% CO2 in nitrogen). The plates were then stained with crystal violet and photographed (left two panels, 1x; right two panels,
light microscopy. The photographs are representatives of 4 cultures. Bar=0.5 mm. Relative cell staining intensity is shown in the middle panel. The
data are average6SD of measuring four fields. (B) F10.9-3 cells (3610
5/well) were cultured in 6-well plates in media without (Ctrl) or with (LAP)
doxycycline. The plates were then cultured either in DMEM or in serum-free EBSS for 100 h and then stained and photographed as in (A). The
photographs are representatives of 4 independent cultures. Bar=0.5 mm. Relative cell staining intensity is shown in the middle panel. The data are
average6SD of measuring four fields.
doi:10.1371/journal.pone.0009516.g009
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was determined by Student’s t-test on the indicated number of
replicates.
RNAi–Mediated Knockdown
siRNA pools (ON-TARGETplus), directed against murine and
human C/EBP-bmRNA (Genebank accession No. NM_009883 and
NM_005194, respectively) were purchased from Dharmacon RNAi
Technologies (Lafayette, CO). The knockdown of the transcripts was
performed in 6-well plates with DharmaFECT 1 reagent, according to
the manufacturer’s protocol. Cells were seeded in media without
antibiotics for the knockdown experiments.
Cell Staining, Fluorescence Microscopy and Flow
Cytometry
To evaluate the extent of cell death, cultures were stained first
with Hoechst 33258 (5 mg/ml, 15 min) washed and stained with
propidium iodide (2.5 mg/ml, 15 min) and then visualized by
Figure 10. LAP attenuates tumor ER stress. (A) Sections of control F10.9-4 tumors and dominant negative LIP-expressing F10.9-4 tumors of
similar sizes, isolated at day 8 (top panels), were immunostained with antibodies against the ER stress marker TRIB3. Nuclei were counter-stained with
Hoechst 33258. The average staining intensity of the red channel (immunostain) was normalized to that of the blue channel (Hoechst 33258). Data
are mean6SD of sections from three tumors (middle top panel). Sections of control F10.9-3 tumors and LAP-expressing F10.9-3 tumors of similar
sizes, isolated at day 8 (bottom panels), were prepared, stained and analyzed as above. Data are mean6SD of sections from 5 tumors. Representative
images are shown. Bar=0.1 mm. (B) The same experiment as in (A), except that the sections were immunostained with antibodies against the ER
stress marker HERPUD. Data are mean6SD of sections from 3 and 4 tumors (middle top and bottom panels, respectively). Representative images are
shown. Bar=0.1 mm.
doi:10.1371/journal.pone.0009516.g010
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were fixed and stained with 5% crystal violet in 66% methanol.
Total cell counts were determined by counting manually, by using
the ImageJ program (NIH) or by reading the crystal violet stained
cultures in 96 well plates with an ELISA reader at 570 nm.
Alternatively, staining intensity was determined in photographs by
the histogram function of Photoshop. For quantitative measure-
ment of viable cells, cultures in 96 well plates were incubated with
Neutral Red (70 mg/L in 0.1 ml DMEM-10, 37uC, 30–60 min),
washed 3X with PBS, re-suspended in lysis buffer (0.1 ml) and OD
was measured with an ELISA reader at 540 nm. A calibration
curve was prepared by seeding known amounts of cells onto 96-
well plates. After 6 h the cells were stained with Neutral Red and
the OD was read as described above. For each experiment,
statistical analyses were performed on the indicated number of
independent experiments using Student’s t-test of the independent
samples. Each independent experiment consisted of 9 replicates.
Apoptosis was evaluated by staining with the rh annexin-V/FITC
kit (Bender MedSystems, Vienna, Austria). Cell cycle analysis was
performed by collecting the cultured cells, fixing in 70% ethanol
on ice, treatment with RNase A (100 mg/ml, 30 min, 37uC),
staining with propidium iodide and flow cytometry.
Immunoblotting of Cellular Proteins
Cells were washed three times with ice-cold phosphate buffered
saline (PBS). Cell pellets were resuspended in two packed cell
volume of lysis buffer (20 mM Hepes, pH 7.9, 0.42 M NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM Phenyl Methyl Sulfonyl
Flouride (PMSF), 0.5 mM dithiothreitol (DTT), 25% glycerol).
The resuspended pellets were then frozen and thawed twice and
kept on ice for 20 min. The lysates were centrifuged (14,000 rpm,
20 min.) and the supernatants containing the cellular proteins
were collected, frozen in liquid nitrogen and stored at 280uC.
Protein concentration was determined by a BCA Protein assay
reagent kit (Pierce, Rockford USA) using bovine serum albumin as
a standard. Protein samples were boiled in SDS-PAGE sample
buffer containing 25 mM DTT, and the supernatants were
resolved by gradient SDS-PAGE (7.5–15% acrylamide). Proteins
were then transferred onto a nitrocellulose membrane, which was
incubated with the indicated antibodies. Second antibody
conjugates were visualized by the Super Signal Detection Kit
(Pierce).
Construction of pcLAP and pcLIP Expression Vectors
To construct a mammalian expression vector that expresses only
LAP (pcLAP), the complete human C/EBP-b ORF was inserted
into pcDNA4 (Life Technologies, Carlsbad CA). Codon 1 (LAP*-
initiating ATG) was point-mutated to CTG using Pfu Turbo DNA
polymerase (Stratagene, La Jolla, CA), the forward oligo 59 TG-
TGCTGGAATTCCCTGCAACGCCTGGTGG and the reverse
oligo 59 ACGGGAAGCCCGCCGCCAGGCCTGCGCCGCC-
GC. Codon 199 (ATG) was then point-mutated as above with the
forward oligo 59 GCGGCGGCGCAGGCCTGGCGGCGGGC-
TTCCCGT and the reverse oligo 59 ACGGGAAGCCCGCCGC-
CAGGCCTGCGCCGCCGC to prevent expression of LIP. The
LIP ORF (codons 199–346) was inserted into pcDNA4 to generate
pcLIP, which expresses only the human LIP isoform of C/EBP-b.
Supporting Information
Figure S1 Inducible over-expression of LAP and LIP in murine
B16 F10.9 clones. B16 F10.9 cells (4610
5/well) were cultured in 6-
well plates with or without doxycycline (Doxy). (A) RT-PCR of C/
EBP-b mRNA from F10-9.3 cells. (B) GFP expression in F10 9.3
cells. Bar=0.5 mm. (C) Dose response of LAP expression in F10
9.3 cells following 24 h treatment with increasing concentrations
of doxycycline, as determined by immunoblotting. (D) Dose
response of LIP expression in F10 9.4 cells, as described in (C).
The gels and blots are representative results of three replicate
experiments.
Found at: doi:10.1371/journal.pone.0009516.s001 (1.00 MB
TIF)
Figure S2 LIP augments and LAP attenuates ER stress-
triggered cell death in a dose-dependent manner. (A) F10.9-4
cells (2610
4/well) were cultured in 96-well plates with the
indicated concentration of doxycycline for 24 h. Diluent (Ctrl),
tunicamycin (Tm) or thapsigargin (Tg) were then added. After an
additional 24 h the plates were stained with crystal violet and
photographed. The photograph is representative of five replicate
experiments. (B) F10.9-3 cells (1.5610
4/well) were cultured in 96-
well plates with the indicated concentration of doxycycline for
24 h. Diluent (Ctrl), tunicamycin (Tm) or thapsigargin (Tg) was
then added. After 24 h the plates were stained with crystal violet
and photographed under a light microscope. Control cells were
also photographed by fluorescent microscopy (top panel) to
evaluate the extent of GFP and C/EBP-b induction by
doxycycline. The photograph is a representative of five replicate
experiments. Bar=0.5 mm.
Found at: doi:10.1371/journal.pone.0009516.s002 (9.92 MB
TIF)
Figure S3 Survival and death of F10.9-3 cells under ER stress.
(A) F10.9-3 cells were seeded in 8 well microscopy chambers
(Integrated Biodiagnostics, Munich, Germany; 40,000/well) and
after 24 h challenged either with tunicamycin (0.5 mg/ml, 24 h) or
with TNF-a (100 ng/ml) plus IFN-c (1000 IU/ml) for 24 h. The
cells were stained for apoptosis by the rh annexin-V/FITC kit
followed by Hoechst 33258. The treatment with TNF-a plus IFN-
c served as a positive control for apoptosis, as determined by the
annexin V/FITC staining. The photographs are representatives of
four replicate studies. Bars are 0.2 mm. Insets: larger magnifica-
tion to show cellular staining details. Bar=0.05 mm. (B) F10.9-3
cells in 6-well plates were challenged with tunicamycin (1 mg/ml,
48 h). The detached cells were collected, plated and stained with
propidium iodide and counter-stained with Hoechst 33258. The
photograph is a representative of three replicate experiments.
Bar=0.2 mm. (C) Control (Ctrl) and doxycycline-treated F10.9-3
cells (LAP) were challenged with tunicamycin (Tm) or Thapsi-
gargin (Tg) as described in Figure 2B. The cells that remained
attached to the plates were stained with crystal violet and
photographed. The photographs are representatives of five
replicate experiments. Bar=0.2 mm.
Found at: doi:10.1371/journal.pone.0009516.s003 (4.02 MB
TIF)
Figure S4 Effects of LAP and LIP knockdown or over-
expression on cell survival upon ER stress. (A) Human 293T cells
in 6 well plates were transfected with 1 mg of control pcDNA4
(middle lane), pcLAP (left lane), or pcLIP (right lane). After 24 h
cell extracts (20 mg protein) were immunoblotted with antibodies
directed to the common C-terminus of C/EBP-b. N.S. is non-
specific bands. The blot is a representative of three replicates. (B)
Human 293T cells were transfected as in E and after 24 h were
trypsin-digested and seeded in poly(D-lysine)-coated 96 well plates
(20,000 cells/well). After additional 24 h the cells were either
untreated (Ctrl) or challenged with tunicamycin (2 mg/ml). The
plates were left for 24 h and the number of viable cells was
determined by the Neutral Red assay. Percent survival represent
the ratio of tunicamicyn-treated to diluent-treated cells. Data are
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PLoS ONE | www.plosone.org 12 March 2010 | Volume 5 | Issue 3 | e9516mean6SD of four replicates. Similar transfection efficiencies were
obtained with the three vectors and cell counts were very similar in
the control cultures not treated with tunicamycin (Ctrl). (C) HeLa
cells (2610
5/well) were cultured in 6-well plates for 24 h and then
transfected with a control siRNA or C/EBP-b-specific siRNA.
After 24 h, RNA was isolated and analyzed by RT-PCR (left
panels), and cell extracts were prepared and analyzed by
immunoblotting with antibodies directed to the common C-
terminus of C/EBP-b (right panels). The gels and blots are
representatives of three replicate experiments. (D) HeLa cells were
seeded and transfected as described in (C). After 36 h, diluent
(Ctrl) or Tunicamycin (Tm) were added and after an additional
31 h the cultures were stained with Crystal Violet and photo-
graphed. The photographs are representatives of four replicate
experiments. Bar=0.5 mm. (E) Cell counts following the treat-
ments described in (D). The data are average of counting four
fields. (F) Human HeLa cells (200,000) were transfected with 1 mg
of either control pcDNA4 vector, pcLAP vector (mutated to
encode LAP only), or pcLIP vector (encoding LIP only). After 24 h
the cells were seeded in 96 well plates (20,000 cells/well) and after
additional 24 h diluent or tunicamycin (4 mg/ml) were added.
After 48 h cell viability was determined by Neutral Red staining.
Percent viability was determined by the ratio of tunicamycin to
diluent-treated cells. Data are mean6SD of six replicates.
Found at: doi:10.1371/journal.pone.0009516.s004 (2.03 MB
TIF)
Acknowledgments
We thank Sergey Bujanover and Sara Barak for their excellent
experimental assistance, Daniela Novick and Joseph Lotem for their
insight and advice, Michel Revel and Judith Chebath for providing the
F10.9 clones and Elazar Zelzer for assistance in immunohistochemistry.
MR is the Edna and Maurice Weiss Professor of Cytokine Research.
Author Contributions
Conceived and designed the experiments: OM MR. Performed the
experiments: OM ED. Analyzed the data: OM ED AW MR. Wrote the
paper: MR.
References
1. Marciniak SJ, Ron D (2006) Endoplasmic reticulum stress signaling in disease.
Physiol Rev 86: 1133–1149.
2. KimI, Xu W, Reed JC (2008) Cell deathand endoplasmic reticulum stress: disease
relevance and therapeutic opportunities. Nat Rev Drug Discov 7: 1013–1030.
3. Chen C, Dudenhausen EE, Pan YX, Zhong C, Kilberg MS (2004) Human
CCAAT/enhancer-binding protein beta gene expression is activated by
endoplasmic reticulum stress through an unfolded protein response element
downstream of the protein coding sequence. J Biol Chem 279: 27948–27956.
4. Chen H, Pan YX, Dudenhausen EE, Kilberg MS (2004) Amino acid deprivation
induces the transcription rate of the human asparagine synthetase gene through
a timed program of expression and promoter binding of nutrient-responsive
basic region/leucine zipper transcription factors as well as localized histone
acetylation. J Biol Chem 279: 50829–50839.
5. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, et al. (1998)
CHOP is implicated in programmed cell death in response to impaired function
of the endoplasmic reticulum. Genes Dev 12: 982–995.
6. Rahman SM, Schroeder-Gloeckler JM, Janssen RC, Jiang H, Qadri I, et al.
(2007) CCAAT/enhancing binding protein beta deletion in mice attenuates
inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-
induced nonalcoholic steatohepatitis. Hepatology 45: 1108–1117.
7. Buck M, Poli V, Hunter T, Chojkier M (2001) C/EBPbeta phosphorylation by
RSK creates a functional XEXD caspase inhibitory box critical for cell survival.
Mol Cell 8: 807–816.
8. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC (2002) CCAAT/enhancer
binding protein-beta is a mediator of keratinocyte survival and skin
tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci U S A
99: 207–212.
9. Sterneck E, Zhu S, Ramirez A, Jorcano JL, Smart RC (2006) Conditional
ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for
cell survival and mouse skin tumorigenesis. Oncogene 25: 1272–1276.
10. Yoon K, Zhu S, Ewing SJ, Smart RC (2007) Decreased survival of C/EBP beta-
deficient keratinocytes is due to aberrant regulation of p53 levels and function.
Oncogene 26: 360–367.
11. Akagi T, Saitoh T, O’Kelly J, Akira S, Gombart AF, et al. (2008) Impaired
response to GM-CSF and G-CSF, and enhanced apoptosis in C/EBP beta -
deficient hematopoietic cells. Blood 111: 2999–3004.
12. Mukherjee D, Kaestner KH, Kovalovich KK, Greenbaum LE (2001) Fas-
induced apoptosis in mouse hepatocytes is dependent on C/EBPbeta.
Hepatology 33: 1166–1172.
13. Cortes-Canteli M, Pignatelli M, Santos A, Perez-Castillo A (2002) CCAAT/
enhancer-binding protein beta plays a regulatory role in differentiation and
apoptosis of neuroblastoma cells. J Biol Chem 277: 5460–5467.
14. Marshall J, Dolan BM, Garcia EP, Sathe S, Tang X, et al. (2003) Calcium
channel and NMDA receptor activities differentially regulate nuclear C/
EBPbeta levels to control neuronal survival. Neuron 39: 625–639.
15. Sun L, Fu BB, Liu DG (2005) Systemic delivery of full-length C/EBP beta/
liposome complex suppresses growth of human colon cancer in nude mice. Cell
Res 15: 770–776.
16. Gade P, Roy SK, Li H, Nallar SC, Kalvakolanu DV (2008) Critical role for
transcription factor C/EBP-beta in regulating the expression of death-associated
protein kinase 1. Mol Cell Biol 28: 2528–2548.
17. Descombes P, Schibler U (1991) A liver-enriched transcriptional activator
protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from
the same mRNA. Cell 67: 569–579.
18. Li Y, Bevilacqua H, Chiribau C-B, Majumder M, Wang C, et al. (2008)
Differential control of the C/EBP beta products LAP and LIP and the regulation
of gene expression during the response to endoplasmic reticulum stress. J Biol
Chem 283: 22443–22456.
19. Lin JH, Walter P, Yen TS (2008) Endoplasmic reticulum stress in disease
pathogenesis. Annu Rev Pathol 3: 399–425.
20. Hersey P, Zhang XD (2008) Adaptation to ER stress as a driver of malignancy
and resistance to therapy in human melanoma. Pigment Cell Melanoma Res 21:
358–367.
21. Rutkowski DT, Kaufman RJ (2007) That which does not kill me makes me
stronger: adapting to chronic ER stress. Trends Biochem Sci 32: 469–476.
22. Moenner M, Pluquet O, Bouchecareilh M, Chevet E (2007) Integrated
endoplasmic reticulum stress responses in cancer. Cancer Res 67: 10631–10634.
23. Li W, Kessler P, Yeger H, Alami J, Reeve AE, et al. (2005) A gene expression
signature for relapse of primary wilms tumors. Cancer Res 65: 2592–2601.
24. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, et al. (2006) Functional
validation of the anaplastic lymphoma kinase signature identifies CEBPB and
BCL2A1 as critical target genes. J Clin Invest 116: 3171–3182.
25. Eaton EM, Hanlon M, Bundy L, Sealy L (2001) Characterization of C/EBPbeta
isoforms in normal versus neoplastic mammary epithelial cells. J Cell Physiol
189: 91–105.
26. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, et al. (2003) A
mechanism of cyclin D1 action encoded in the patterns of gene expression in
human cancer. Cell 114: 323–334.
27. Shimizu Y, Kishimoto T, Ohtsuka M, Kimura F, Shimizu H, et al. (2007)
CCAAT/enhancer binding protein-beta promotes the survival of intravascular
rat pancreatic tumor cells via antiapoptotic effects. Cancer Sci 98: 1706–1713.
28. Arnett B, Soisson P, Ducatman BS, Zhang P (2003) Expression of CAAT
enhancer binding protein beta (C/EBP beta) in cervix and endometrium. Mol
Cancer 2: 21.
29. Regalo G, Canedo P, Suriano G, Resende C, Campos ML, et al. (2006)
C/EBPbeta is over-expressed in gastric carcinogenesis and is associated with
COX-2 expression. J Pathol 210: 398–404.
30. Homma J, Yamanaka R, Yajima N, Tsuchiya N, Genkai N, et al. (2006)
Increased expression of CCAAT/enhancer binding protein beta correlates with
prognosis in glioma patients. Oncol Rep 15: 595–601.
31. Wessells J, Yakar S, Johnson PF (2004) Critical prosurvival roles for C/EBP beta
and insulin-like growth factor I in macrophage tumor cells. Mol Cell Biol 24:
3238–3250.
32. Sebastian T, Johnson PF (2006) Stop and go: anti-proliferative and mitogenic
functions of the transcription factor C/EBPbeta. Cell Cycle 5: 953–957.
33. Halterman MW, De Jesus C, Rempe DA, Schor NF, Federoff HJ (2008) Loss of
c/EBP-beta activity promotes the adaptive to apoptotic switch in hypoxic
cortical neurons. Mol Cell Neurosci 38: 125–137.
34. Kamaraju AK, Adjalley S, Zhang P, Chebath J, Revel M (2004) C/EBP-delta
induction by gp130 signaling. Role in transition to myelin gene expressing
phenotype in a melanoma cell line model. J Biol Chem 279: 3852–3861.
35. Brewer JW, Hendershot LM, Sherr CJ, Diehl JA (1999) Mammalian unfolded
protein response inhibits cyclin D1 translation and cell-cycle progression. Proc
Natl Acad Sci U S A 96: 8505–8510.
36. Bustin M (2002) At the Crossroads of Necrosis and Apoptosis: Signaling to
Multiple Cellular Targets by HMGB1. Sci STKE 2002: pe39.
37. Endl E, Gerdes J (2000) The Ki-67 protein: fascinating forms and an unknown
function. Exp Cell Res 257: 231–237.
C/EBP-b Regulates Cell Death
PLoS ONE | www.plosone.org 13 March 2010 | Volume 5 | Issue 3 | e951638. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H (2005) TRB3, a novel ER
stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in
cell death. Embo J 24: 1243–1255.
39. Kokame K, Agarwala KL, Kato H, Miyata T (2000) Herp, a new ubiquitin-like
membrane protein induced by endoplasmic reticulum stress. J Biol Chem 275:
32846–32853.
40. Lee AS, Hendershot LM (2006) ER stress and cancer. Cancer Biol Ther 5:
721–722.
41. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, et al. (2008) Preferential
cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of
endoplasmic reticulum stress pathways. Cancer Res 68: 9323–9330.
42. Bundy LM, Sealy L (2003) CCAAT/enhancer binding protein beta (C/
EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial
to mesenchymal transition in culture. Oncogene 22: 869–883.
43. Buck M, Turler H, Chojkier M (1994) LAP (NF-IL-6), a tissue-specific
transcriptional activator, is an inhibitor of hepatoma cell proliferation.
EMBO J 13: 851–860.
44. Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, et al.
(2006) Inducible activation of CEBPB, a gene negatively regulated by BCR/
ABL, inhibits proliferation and promotes differentiation of BCR/ABL-
expressing cells. Blood 107: 4080–4089.
45. Pirot P, Ortis F, Cnop M, Ma Y, Hendershot LM, et al. (2007) Transcriptional
regulation of the endoplasmic reticulum stress gene chop in pancreatic insulin-
producing cells. Diabetes 56: 1069–1077.
C/EBP-b Regulates Cell Death
PLoS ONE | www.plosone.org 14 March 2010 | Volume 5 | Issue 3 | e9516